Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT001 in Healthy Volunteers and Adult Patients With Atopic Dermatitis
NCT06808477Phase 1Recruiting
- Sponsor
- Bambusa Therapeutics
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of BBT001 in atopic dermatitis (AD) (11 arms), sponsored by Bambusa Therapeutics. Primary endpoints: Adverse Events, Change in serum blood parameters and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
BBT001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06808477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808477.